Global Manufacturers of 3-(4-Chlorobutanoyl)Indole-5-Carbonitrile: Technical & Commercial Insights
- High-purity 3-(4-chlorobutanoyl)-1H-indole-5-carbonitrile is a critical intermediate in CNS drug synthesis, requiring stringent control over reaction yield and impurity profiles.
- Industrial purity ≥98% with full COA documentation is essential for regulatory compliance in GMP environments.
- NINGBO INNO PHARMCHEM CO.,LTD. offers scalable manufacturing via optimized synthesis routes, supporting multi-kilogram to metric-ton orders with consistent quality.
As pharmaceutical R&D intensifies around serotonin modulators and next-generation antidepressants, demand for advanced intermediates like 3-(4-chlorobutanoyl)-1H-indole-5-carbonitrile (CAS: 276863-95-7) has surged globally. This compound—also referenced as 3-(4-chloro-butyryl)-1H-indole-5-carbonitrile or 3-(4-Chloro-1-oxobutyl)-1H-indole-5-carbonitrile in technical literature—serves as a pivotal building block in the synthesis of complex indole-based APIs. Unlike its structural analog 3-(4-chlorobutyl)indole-5-carbonitrile (CAS 143612-79-7), which features a reduced alkyl chain, the butanoyl variant contains a reactive ketone moiety, enabling further functionalization via nucleophilic addition or reductive amination.
Synthesis Route and Industrial Purity Standards
The commercial viability of 3-(4-chlorobutanoyl)indole-5-carbonitrile hinges on a robust, reproducible synthesis route that maximizes yield while minimizing genotoxic impurities. Leading manufacturers employ Friedel-Crafts acylation of 5-cyanoindole with 4-chlorobutanoyl chloride under controlled Lewis acid catalysis (e.g., AlCl₃ or FeCl₃), followed by rigorous aqueous workup and crystallization. This approach typically achieves isolated yields exceeding 75% with HPLC purity ≥98.5%.
For B2B buyers, industrial purity is non-negotiable. Specifications must include:
- HPLC/GC purity ≥98%
- Residual solvent levels compliant with ICH Q3C
- Heavy metals <10 ppm
- Water content (KF) ≤0.5%
- Full Certificate of Analysis (COA) with NMR, MS, and HPLC chromatograms
Such standards ensure seamless integration into downstream processes without costly purification steps. When sourcing high-purity global manufacturer partners must demonstrate cGMP-aligned documentation and batch-to-batch consistency.
Evaluating Vendor Reliability: Capacity, Certification, and Lead Times
Not all suppliers can deliver kilogram-scale quantities with pharmaceutical-grade reliability. Key evaluation criteria include:
| Criteria | Minimum Requirement | Ideal Benchmark |
|---|---|---|
| Manufacturing Capacity | ≥10 kg/month | ≥100 kg/month with multi-ton scalability |
| Certifications | ISO 9001 | ISO 9001 + REACH + DMF availability |
| Lead Time (Bulk) | 4–6 weeks | 2–3 weeks with in-stock inventory |
| COA Transparency | Basic assay & identity | Full spectral data + impurity profiling |
Suppliers lacking in-house R&D often outsource synthesis, leading to variability in 3-(4-chlorobutyryl)-1H-indol-5-carbonitrile quality. In contrast, vertically integrated manufacturers control raw material sourcing, reaction optimization, and final QC—ensuring reproducibility across batches.
Custom Synthesis vs. Off-the-Shelf Procurement
While catalog suppliers offer milligram to gram quantities at premium prices (often >$200/g), these are impractical for process development or clinical trial material production. Bulk procurement from a dedicated global manufacturer reduces cost per gram by up to 90%, especially when leveraging existing validated manufacturing process infrastructure.
NINGBO INNO PHARMCHEM CO.,LTD. exemplifies this model. With a dedicated heterocyclic chemistry unit, the company provides both standard and custom-synthesized 3-(4-chlorobutanoyl)-1H-indole-5-carbonitrile under strict quality protocols. Their facility supports:
- Kilo-lab to pilot plant scale (1–100 kg)
- Process optimization for improved yield and reduced E-factor
- Regulatory support including CEP or ASMF documentation upon request
- Stable supply chain with nitrogen-blanketed storage at 2–8°C to prevent degradation
This capability is particularly valuable for innovator pharma companies developing vilazodone analogs or novel 5-HT₁A partial agonists, where consistent intermediate quality directly impacts API efficacy and safety.
Conclusion: Prioritize Technical Excellence in Sourcing
In the competitive landscape of advanced pharmaceutical intermediates, selecting a partner like NINGBO INNO PHARMCHEM CO.,LTD.—a premier global manufacturer with deep expertise in indole chemistry—ensures access to high-purity 3-(4-chlorobutanoyl)indole-5-carbonitrile backed by scalable synthesis, rigorous COA, and responsive technical support. As drug developers accelerate timelines, reliable bulk supply of structurally complex intermediates becomes a strategic advantage, not just a procurement decision.